Company announcement, 12 February 2021 at 7:00 a.m. GMT / 9:00 a.m. EET
Inside information
TURKU - FINLAND - Faron Pharmaceuticals Oy (First North: FARON, AIM: FARN), the clinical stage biopharmaceutical company, announces today that the Bookbuild, announced on 11 February 2021, is now closed. The Placing comprises the issue of 3,521,127 Placing Shares at an Issue Price of €4.26 per Placing Share, which represents a 5% discount to the 30 day volume weighted average price on NASDAQ Helsinki First North Growth.
The Placing Shares to be issued amount to approximately 7.5 per cent of the issued shares and votes in the Company, immediately prior to the Placing. The Company raised aggregate gross proceeds of EUR 15 million in the Placing. Several new high-quality Continental European institutional investors participated in the Placing, expanding Faron's investor base, along with existing investors, as planned. The European Investment Council Fund, EIC, which had given a pre-commitment, was the largest of the new investors. Faron is the first publicly listed company that the EIC Fund has invested in.
After all of the media coverage over the week end I really thought ABDX would come out with a clear and defined reply to the coverage. Coverage that is robust and reassuring. Not a '' I refer the right Honourable Gentleman to the answer I gave earlier...''
Shame its such a very weak response.
York, U.K. 8 February 2021: Abingdon Health plc (AIM: ABDX) ("the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, notes the article published in the Daily Mail on 6 February 2021 and refers investors to the RNS announcements made on 29 December 2020, 26 January 2021 and 27 January 2021 which accurately reflect the Company's position and current performance.
01 February 2021
IDE Group Holdings plc, the mid-market network, cloud and IT managed services provider, provides a trading update for the year ended 31 December 2020. As indicated at the time of the Group's interim results in September, revenue and EBITDA in the second half of the year were slightly down on the first half, and IDE expects to report revenue of £23.6 million (FY19: £28.2 million) and Adjusted EBITDA* of approximately £0.5 million (FY19: £1.1 million) for the year ended 31 December 2020.
Is this a new Shares Magazine article today, as the RNS is dated 3rd November 2020 and after the original release the shares remained flat at 75p according the HL ODX News. It looks all positive but I don't see anything new ?
Full agree DaveBoy, having faith in the Directors and their own buys always helps me to relax over any minor short term fluctuations.
21st Jan 2021 5:41 pm RNS Director/PDMR Shareholding
19th Jan 2021 2:20 pm RNS Director/PDMR Shareholding
: ) GLA
Hi V_W,
The trade is not shown as an uncrossing trade UT, so I am hoping its a buy this afternoon. However, the MM may well have put it down as a BUY when actually it was an early AM SELL. It's all very cloak and dagger at times. In my mind its a BUY : )
S.
A POSITIVE RNS AND RESULTS FROM THE CHIEF EXECUTIVE Dr. Mariola Soehngen.
"The Company made good progress in 2020 and we were able to deliver results in line with the indications outlined in our H1 2020 report. The improved cash position at the end of 2020 provides a good platform for the new year and the substantial order book value we are carrying forward puts our service business in a strong position for 2021. We expect that the traction we are seeing on key partnerships developed in 2020 will continue.
Finally I would like to stress that I joined the company in September 2020 convinced that there is excellent potential in our business and markets. Proteomics is increasingly being regarded an integral part of research and development projects, so we expect the demand to increase further. I am excited to be on board, very pleased with the capability of the business and our people and convinced we have a bright future. We have begun a re-evaluation of our strategy and will evaluate both organic and external opportunities. I look forward to interacting with our shareholders and all other stakeholders and am convinced of the opportunity to create value for all constituents.
Great news to have cash in the bank and receive such positive comments from the Chief. I look forward to the Chief Executive's next update.
A good start to the week. GLA